Numerous clinical trials evaluate the efficacy and safety of ridaforolimus as monotherapy or in combination with chemotherapy or biologics across diverse oncological and cardiovascular conditions, including advanced solid tumors, non-small cell lung cancer, endometrial cancer, ovarian cancer, lymphoma, multiple myeloma, and coronary stenosis. Spanning Phase 1 through Phase 3 development, these studies are sponsored by pharmaceutical companies and academic institutions. The trials encompass various recruitment statuses, including completed, active, recruiting, suspended, terminated, and withdrawn.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06410313 | RECRUITING | Superficial Femoral Artery Stenosis; Popliteal Artery Stenosis |
Medinol Ltd. |
2024-08-15 | |
| NCT06071702 | SUSPENDED | Coronary Stenosis; Coronary Artery Disease |
Medinol Ltd. |
2025-08-07 | |
| NCT05364697 | ACTIVE_NOT_RECRUITING | Coronary Stenosis; Coronary Disease; Non-ST Elevated Myocardial Infarction; Cardiovascular Diseases |
Medinol Ltd. |
2022-08-30 | |
| NCT03702608 | COMPLETED | Coronary Stenosis |
Medinol Ltd. |
2018-11-14 | |
| NCT02828917 | COMPLETED | de Novo or Restenosis Lesions |
Medinol Ltd. |
2017-01-16 | |
| NCT00836927 | TERMINATED | Advanced Cancers |
Merck Sharp & Dohme LLC |
2009-02-01 | PHASE2 |
| NCT02834806 | COMPLETED | Stenosis |
Medinol Ltd. |
2016-09 | |
| NCT01995487 | COMPLETED | Coronary Artery Stenosis |
Medinol Ltd. |
2014-01 | |
| NCT01256268 | COMPLETED | Endometrial Cancer; Ovarian Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2011-06-13 | PHASE1 |
| NCT01995500 | COMPLETED | Coronary Artery Stenosis |
Medinol Ltd. |
2014-03-19 | PHASE2 |
| NCT01169532 | COMPLETED | Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific |
Fox Chase Cancer Center |
2010-10 | PHASE1 |
| NCT01605396 | COMPLETED | Breast Neoplasms |
Merck Sharp & Dohme LLC |
2012-07-04 | PHASE2 |
| NCT01295632 | COMPLETED | Advanced Cancer |
Merck Sharp & Dohme LLC |
2011-02 | PHASE1 |
| NCT01234857 | COMPLETED | Breast Cancer |
Merck Sharp & Dohme LLC |
2010-09-17 | PHASE2 |
| NCT01431547 | COMPLETED | Solid Tumors |
Merck Sharp & Dohme LLC |
2012-02 | PHASE1 |
| NCT01431534 | TERMINATED | Solid Tumors |
Merck Sharp & Dohme LLC |
2012-01-30 | PHASE1 |
| NCT01243762 | TERMINATED | Neoplasms Malignant |
Merck Sharp & Dohme LLC |
2010-11-22 | PHASE1 |
| NCT01212627 | TERMINATED | Non-Small Cell Lung Cancer |
Angela Taber MD |
2010-09 | PHASE1 |
| NCT01220570 | COMPLETED | Breast Cancer |
Merck Sharp & Dohme LLC |
2010-09 | PHASE1 |
| NCT00818675 | TERMINATED | Non-Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2009-03 | PHASE2 |
| NCT00770185 | COMPLETED | Endometrial Cancer |
NCIC Clinical Trials Group |
2008-11-13 | PHASE2 |
| NCT01431547 | Completed | Solid Tumors |
Merck Sharp & Dohme LLC |
2012-02 | Phase 1 |
| NCT01431534 | Terminated | Solid Tumors |
Merck Sharp & Dohme LLC |
2012-01-30 | Phase 1 |
| NCT01380184 | COMPLETED | Cancer, Advanced |
Merck Sharp & Dohme LLC |
2011-07-05 | PHASE1 |
| NCT01010672 | COMPLETED | Sarcoma |
Merck Sharp & Dohme LLC |
2009-11 | PHASE2 |
| NCT01296659 | WITHDRAWN | Soft Tissue Sarcoma |
The University of Texas Health Science Center at San Antonio |
2011-02 | PHASE1 |
| NCT01380184 | Completed | Cancer Advanced |
Merck Sharp & Dohme LLC |
2011-07-05 | Phase 1 |
| NCT00777959 | COMPLETED | Prostate Cancer |
Merck Sharp & Dohme LLC |
2008-10 | PHASE2 |
| NCT00739830 | COMPLETED | Endometrial Cancer |
Merck Sharp & Dohme LLC |
2008-08 | PHASE2 |
| NCT01295632 | Completed | Advanced Cancer |
Merck Sharp & Dohme LLC |
2011-02 | Phase 1 |
| NCT00736970 | COMPLETED | Breast Cancer; Breast Neoplasms |
Merck Sharp & Dohme LLC |
2008-07 | PHASE2 |
| NCT00730379 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2008-07 | PHASE1 |
| NCT00538239 | COMPLETED | Metastatic Soft-Tissue Sarcomas; Metastatic Bone Sarcomas |
Merck Sharp & Dohme LLC |
2007-10 | PHASE3 |
| NCT01071304 | COMPLETED | Relapsed or Refractory Advanced Cancer |
Merck Sharp & Dohme LLC |
2010-03 | PHASE1 |
| NCT01212627 | Terminated | Non-Small Cell Lung Cancer |
Angela Taber MD|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Roger Williams Medical Center|Brown University |
2010-09 | Phase 1 |
| NCT00704054 | COMPLETED | Solid Tumors |
Merck Sharp & Dohme LLC |
2008-01 | PHASE1 |
| NCT01043887 | COMPLETED | Healthy Volunteers; Hepatic Insufficiency |
Merck Sharp & Dohme LLC |
2010-01 | PHASE1 |
| NCT00781846 | COMPLETED | Solid Tumor |
Merck Sharp & Dohme LLC |
2008-10 | PHASE1 |
| NCT00874731 | COMPLETED | Metastatic or Locally Advanced Cancer |
Merck Sharp & Dohme LLC |
2009-04-28 | PHASE1 |
| NCT00694083 | COMPLETED | Neoplasm |
Merck Sharp & Dohme LLC |
2008-06-10 | PHASE1 |
| NCT00112372 | COMPLETED | Cancer |
Merck Sharp & Dohme LLC |
2005-05 | PHASE1 |
| NCT00093080 | COMPLETED | Leiomyosarcoma; Liposarcoma; Osteosarcoma; Sarcoma, Soft Tissue; Metastases |
Merck Sharp & Dohme LLC |
2004-10 | PHASE2 |
| NCT00288431 | COMPLETED | Cancer; Sarcoma |
Merck Sharp & Dohme LLC |
2006-02 | PHASE1 |
| NCT00122343 | COMPLETED | Endometrial Cancer |
Merck Sharp & Dohme LLC |
2005-08 | PHASE2 |
| NCT00110188 | COMPLETED | Prostate Cancer |
Merck Sharp & Dohme LLC |
2005-05 | PHASE2 |
| NCT00086125 | COMPLETED | Hematologic Malignancies; Leukemia; Myelodysplastic Syndromes; Myeloid Metaplasia; Lymphoma |
Merck Sharp & Dohme LLC |
2004-06 | PHASE2 |
| NCT00060645 | COMPLETED | Tumors; Lymphoma; Multiple Myeloma |
Merck Sharp & Dohme LLC |
2003-05 | PHASE1 |
| NCT00060632 | COMPLETED | Tumors; Lymphoma; Multiple Myeloma |
Merck Sharp & Dohme LLC |
2003-04 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2025-09-22)
Check the
Ridaforolimus (Deforolimus, MK-8669)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Ridaforolimus (Deforolimus, MK-8669) Solubility in DMSO
- Ridaforolimus (Deforolimus, MK-8669) Stock Solution
- Ridaforolimus (Deforolimus, MK-8669) Storage
- Ridaforolimus (Deforolimus, MK-8669) Stability
- Ridaforolimus (Deforolimus, MK-8669) Molecular Weight
- Ridaforolimus (Deforolimus, MK-8669) SMILES
- Ridaforolimus (Deforolimus, MK-8669) CAS Number
- Ridaforolimus (Deforolimus, MK-8669) Chemical Structure (2D and 3D)
- Ridaforolimus (Deforolimus, MK-8669) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.